Amneal asks FDA to approve another new formulation of Parkinson’s combo drug

Kyle LaHucik

Senior Reporter

After having already received FDA approval for a carbidopa/levodopa combination in 2015, Amneal Pharmaceuticals is again at the regulator’s doorstep with another new combination of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Amneal asks FDA to approve another new formulation of Parkinson’s combo drug

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials

Am­neal asks FDA to ap­prove an­oth­er new for­mu­la­tion of Parkin­son’s com­bo drug

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

more like this

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

Amneal asks FDA to approve another new formulation of Parkinson’s combo drug

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials